Table 4.
Clinical characteristics of subjects (n = 937) according to the locational predominance of cerebral WMH.
| No WMH (n = 351) | Pred-PVWMH (n = 114) | Pred-DSWMH (n = 78) | Both PVWMH and DSWMH (n = 394) | p | |
|---|---|---|---|---|---|
| Gender (male, %) | 142 (40.5) | 52 (45.6) | 24 (30.8) | 136 (34.5) | 0.059 |
| Age, year | 63.2 ± 6.0 | 68.0 ± 5.9 | 64.7 ± 5.9 | 68.7 ± 5.9 | <0.001 |
| Hypertension (%) | 174 (49.6) | 57 (50.0) | 46 (59.0) | 273 (69.3) | <0.001 |
| Diabetes mellitus (%) | 65 (18.5) | 30 (26.3) | 14 (17.9) | 111 (28.2) | 0.009 |
| Hypercholesterolemia (%) | 116 (33.0) | 34 (29.8) | 25 (32.1) | 132 (33.5) | 0.902 |
| Current smoking status (%) | 72 (20.5) | 23 (20.2) | 12 (15.4) | 77 (19.5) | 0.780 |
| CAOD (%) | 19 (5.4) | 12 (10.5) | 0 (0.0) | 22 (5.6) | 0.020 |
| Statin medication (%) | 90 (25.6) | 24 (21.1) | 18 (23.1) | 90 (22.8) | 0.717 |
| SBP, mmHg | 130.9 ± 15.4 | 131.6 ± 18.6 | 130.6 ± 18.6 | 135.3 ± 20.1 | 0.006 |
| DBP, mmHg | 80.3 ± 10.9 | 78.9 ± 10.5 | 78.5 ± 11.1 | 81.0 ± 12.2 | 0.161 |
| Glucose, mg/dL | 124.8 ± 43.9 | 128.8 ± 47.3 | 128.9 ± 53.2 | 127.2 ± 54.2 | 0.819 |
| Total cholesterol, mg/dL | 194.2 ± 37.2 | 193.6 ± 48.7 | 199.3 ± 41.5 | 190.8 ± 41.2 | 0.350 |
| Triglyceride, mg/dL | 150.8 ± 101.6 | 142.0 ± 86.3 | 160.7 ± 97.7 | 156.6 ± 101.9 | 0.471 |
| eGFR, ml/min/1.73 m2 | 77.3 ± 15.4 | 71.6 ± 19.7 | 73.3 ± 14.0 | 71.2 ± 17.8 | <0.001 |
| Hcyt, IU/L | 10.0 ± 3.5 | 12.0 ± 6.1 | 9.6 ± 3.4 | 11.7 ± 5.3 | <0.001 |
pred-PVWMH, predominant periventricular white matter hyperintensities; pred-DSWMH, predominant deep subcortical white matter hyperintensities; CAOD, coronary arterial occlusive disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hcyt, plasma total homocysteine.